论文部分内容阅读
氨联吡啶酮(Amrinone,AMR)由美国Ssterling-Winthrop实验室的Lesher和Opolka于1978年首次合成,化学名称为5氨基-3.4二吡啶-6(1-H)-酮。动物实验和临床试验表明,该药具有强心和扩血管的双重作用,有利于心力衰竭患者血流动力学状况的改善。然究其改善血流动力学状况的机制,几乎无不认为赖其正性肌力作用。至于AMR的扩血管效应,虽然说法不一,但多认为继发于正性肌力作用。很多研究者虽承认AMR的直接扩血管作用及其对血流动力学状况的改善所
Amrinone (AMR) was first synthesized in 1978 by Lesher and Opolka of the Ssterling-Winthrop Laboratory in the United States and has the chemical name 5amino-3,4-dipyridin-6 (1-H) -one. Animal experiments and clinical trials show that the drug has the dual effects of cardia and vasodilator, and is beneficial to the improvement of hemodynamics in patients with heart failure. However, its mechanism to improve hemodynamic status, almost all thought that its positive inotropic effect. As for the vasodilator effect of AMR, although different, but considered secondary to positive inotropic effect. Although many researchers acknowledge the direct vasodilatory effect of AMR and its improvement in hemodynamic status